Skip to main content
. Author manuscript; available in PMC: 2014 Jan 18.
Published in final edited form as: J Biomech. 2012 Dec 6;46(2):338–344. doi: 10.1016/j.jbiomech.2012.11.033

Fig. 3.

Fig. 3

Comparison of platelet activity reduction achieved by optimization to that achieved by two common antithrombotic agents – Aspirin (ASA) and Dipyridamole. Platelet Activation Rate (PAR) in the optimized (top) and non-optimized VAD+antocoagulation (bottom): platelets (left) and platelets + RBC (right). The non-optimized VAD is the control (red), optimization (blue) ASA (green) Dipyridamole (blue), correspondingly.